← back to search

Joseph Meserve

University of California San Diego · US
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Eosinophilic Esophagitis, and Biosimilars and Bioanalytical Methods.
h-index
15
citations
1,354
works
55
NIH funding
primary concept
email

Recent publications

The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti‐<scp>TNF</scp> Therapy: A Multicentre Study
Alimentary Pharmacology & Therapeutics 2025cited by 11position: middledoi
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis
Clinical Gastroenterology and Hepatology 2021cited by 62position: firstdoi
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Clinical Gastroenterology and Hepatology 2020cited by 79position: middledoi
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases
Alimentary Pharmacology & Therapeutics 2020cited by 76position: firstdoi
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
Clinical Gastroenterology and Hepatology 2020cited by 59position: middledoi
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
Clinical Gastroenterology and Hepatology 2019cited by 69position: middledoi
Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
The American Journal of Gastroenterology 2018cited by 175position: middledoi
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease
Gastroenterology 2018cited by 147position: middledoi
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Clinical Gastroenterology and Hepatology 2018cited by 81position: firstdoi
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases 2018cited by 76position: middledoi
OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
Journal of Crohn s and Colitis 2018cited by 13position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Siddharth Singh · Bennett University2 papers (2020–2021)Ali Bessissow · Society of Interventional Radiology1 papers (2025–2025)Russell Yanofsky · McGill University Health Centre1 papers (2025–2025)Zubin Lahijanian · McGill University Health Centre1 papers (2025–2025)Siddharth Singh · Banaras Hindu University1 papers (2025–2025) · 1 papers (2025–2025) · 1 papers (2025–2025) · 1 papers (2025–2025)Ranjeeta Mallick · Royal Ottawa Mental Health Centre1 papers (2025–2025)Talal Alenezi · McGill University Health Centre1 papers (2025–2025)Tim Ramsay · Stantec (Canada)1 papers (2025–2025)Vipul Jairath · Western University1 papers (2021–2021)Antonio Facciorusso · Collaborative Group (United States)1 papers (2020–2020) · 1 papers (2025–2025)Greg Rosenfeld · University of British Columbia Hospital1 papers (2025–2025)Blair Macdonald · McMaster University1 papers (2025–2025)David H. Bruining · Mayo Clinic1 papers (2025–2025)Vito Annese · Vita-Salute San Raffaele University1 papers (2020–2020)Parambir S. Dulai · Northwestern University1 papers (2021–2021)Talat Bessissow · McGill University Health Centre1 papers (2025–2025)